Document is current
Any future updates will be listed below
-
Authors
Srikor, Sirawit https://orcid.org/0009-0008-1528-3441
Sungnak, Waradon https://orcid.org/0000-0002-0136-4960
Trakoolsoontorn, Chawinya
Poonpanichakul, Tiraput https://orcid.org/0000-0002-3651-3575
Jiravejchakul, Natnicha
Jevapatarakul, Damita https://orcid.org/0000-0002-8126-6964
Thungsatianpun, Narita
Opasawatchai, Anunya
Dratva, Lisa
Kretschmer, Lorenz https://orcid.org/0000-0003-0987-8429
,
Sakuntabhai, Anavaj
Singhasivanon, Pratap
Suraamornkul, Swangjit
Yingtaweesak, Tawatchai
Manopwisedjaroen, Khajohnpong
Pitabut, Nada
Thaloengsok, Sasikanya
Pakchotanon, Pattarakul
Matangkasombut, Oranart
Screaton, Gavin https://orcid.org/0000-0002-3549-4309
Dejnirattisai, Wanwisa
Duangchinda, Thaneeya
Park, Jongeun https://orcid.org/0000-0002-1687-2423
Meyer, Kerstin
Mongkolsapaya, Juthathip
Charoensawan, Varodom https://orcid.org/0000-0002-2199-4126
Teichmann, Sarah A. https://orcid.org/0000-0002-6294-6366
Matangkasombut, Ponpan https://orcid.org/0000-0003-0101-4386
- License Information
-
More Information
Article History
Received: 28 August 2025
Accepted: 13 May 2026
First Online: 3 June 2026
Competing interests
: S.A.T. is a scientific advisory board member of ForeSite Labs, OMass Therapeutics, Qiagen, Xaira Therapeutics, a co-founder and equity holder of TransitionBio and Ensocell Therapeutics, a non-executive director of 10x Genomics and a part-time employee of GlaxoSmithKline. The remaining authors declare no competing interests.
